Kornimate/medical-research-clean huggingface dataset:
does perioperative intravenous magnesium affect postoperative quality of recovery in craniotomy surgery patients?

Conditions: Brain Tumor; Surgery

Summary: perioperative pain management for craniotomy patients may be challenging because the commonly used agents such as opioids, gabapentin, and dexmedetomidine also cause sedation, which can confound the neurological exam and can lead to respiratory depression and increased intracranial pressure. preoperative intravenous magnesium boluses and infusions have previously been established as an effective, nonsedating analgesic that can reduce opioid consumption 25-30% up to 48 hours postoperatively. however, intravenous magnesium has not seen widespread use in craniotomy patients due to concerns for interference with the neurological monitoring that commonly occurs in these cases. intravenous magnesium given as a bolus preoperatively or as a constant infusion may avoid these problems and has never been investigated. the goal of this study is to compare intravenous magnesium given preoperatively and intraoperatively to placebo in adult elective craniotomy patients to improve quality of recovery postoperatively, and evaluate safety and tolerability. secondary endpoints will include evaluating for pain, sedation, agitation, blood pressure, and opioid consumption postoperatively.

the study is a prospective, randomized, controlled, and double-blinded clinical trial comparing clinical outcomes of craniotomy patients who a magnesium infusion of 15mg/kg/hr to a placebo group of patients who will receive a saline bolus and infusion of equivalent volume starting at surgical closure and continuing for 15 hours. the sample size calculations are based on an effect size 24 point increase in quality of recovery-40 questionnaire scores from a previous randomized control trial featuring the same bolus and infusion regimen as this trial. investigators, patients, and providers will be blinded. patients over the age of 18 undergoing elective craniotomy surgery will be enrolled. the study population will consist of patients undergoing elective craniotomy surgery. the inclusion criteria consists of patient age 18-85, asa (american society of anesthesiologists) physical status classification 1-3, with glasgow coma scale (gcs) of 15 with adequate english comprehension. exclusion criteria includes pregnant or nursing patients, patients with known allergies to any of the study drugs, patient's refusal, patients with a history of cirrhosis, chronic kidney disease stage 3 or higher, known history of substance abuse, neuromuscular disease or heart block.

Eligibility criteria:
inclusion criteria: * patient age 18-85 * asa (american society of anesthesiologists) physical status classification 1-3 * glasgow coma scale (gcs) of 15 * adequate english comprehension exclusion criteria: * pregnant or nursing patients * patients with known allergies to any of the study drugs * patient's refusal * patients with a history of cirrhosis * chronic kidney disease stage 3 or higher * known history of substance abuse * history of neuromuscular disease * history of heart block
prevalence of hepatitis b infection in the galilee region, israel

Conditions: Hepatitis B

Summary: primary aims: 1. evaluate hbv (hepatitis b virus) infection prevalence among druze in the galilee. 2. educate the population in order to reduce transmission 3. increase awareness among primary care providers secondary aims: 1. identify chronic hbv infected patients who need to be followed and treated, 2. identify hbv infected women in a childbearing age 3. identify non immunized individuals and recommend vaccination 4. identify previously vaccinated individuals who are not immunized 5. identify previously vaccinated individuals who became infected study design: study population is targeted to native israeli druze. we aim for evaluating up to 20,000 people from druze communities in the galilee area this work will be divided into three sections: 1. increasing awareness: lectures and local events will be taken place in the communities. written information will be given and primary care-providers mainly family doctors, nurses and obstetric surgeons will be involved. 2. all participants, upon signing a consent will: * fill up a questioner * checked for weight, height and waist circumflex * have a blood sample taken 3. results and recommendations will be forwarded to all participants


Eligibility criteria:
inclusion criteria: * all consent adults who are 18 year old or older exclusion criteria: * individuals younger than 18 year old * individuals who cannot or will not sign consent

Keywords: hepatitis b prevalence hbsag vaccination galilee
determining the glycemic effects of sunflower pasta

Conditions: Potential Abnormality of Glucose Tolerance; Appetitive Behavior

Summary: this study investigated the effects of five types of pasta on the glycemic responses

this study aimed to 1.determine the glycemic index and glycemic load of five types of pasta (tagliatella control, 5% sunflower tagliatella, 16% sunflower tagliatella, 16% sunflower penne and 16% sunflower fusilli) and 2. investigate the effects of these pasta types on postprandial glycemic responses in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy * non-smoking * non-diabetic men and women * body mass index between 18 and 25 kg/m2 exclusion criteria: * severe chronic disease (e.g. cardiovascular diseases, diabetes mellitus, kidney or liver conditions, endocrine conditions) * gastrointestinal disorders * pregnancy * lactation * competitive sports * alcohol abuse * drug dependency

Keywords: blood glucose pasta glycemic index glycemic load
dat spect and procedural motor skills in parkinson's disease

Conditions: Parkinson Disease

Summary: patients with parkinson's disease (pd) are known to be affected by subtle cognitive impairment early in the disease course, mostly in the executive field. procedural motor skills, mainly controlled by the basal ganglia associative loop (in particular dorsal caudate nucleus) (rodriguez-oroz et al., 2009), have also been studied in patients with pd (schnider et al., 1995; muslimovic et al., 2007; terpening et al., 2013). however, the correlation of dopaminergic 123i-fp-cit spect imaging and cognitive impairment has not been assessed. one reason is the absence of reference values for striatal uptake until recently. last year, the investigators established local uptake reference values for dat imaging based on a large cohort of subjects with non-degenerative conditions (nicastro et al., 2016) and can therefore use these values to precisely assess uptake loss in patients with pd. with the present study, the investigators expect to enroll patients with early pd for whom a 123i-fp-cit spect has been previously performed in the center. subjects will perform a specific motor task based on mirror-drawing of star-shaped figures. this will be done by inverting the direction of horizontal/vertical computer mouse movements on the screen. speed and error rates will be assessed for patients as well as healthy control subjects. correlation with striatal spect uptake, especially caudate nucleus uptake, will be analyzed for pd patients. in addition, resting-state eeg will be performed for all subjects. general medication and dopaminergic drugs in particular, whenever used, will not be discontinued. for all subjects enrolled in the study, cognitive and neurological examination will be performed.


Eligibility criteria:
inclusion criteria for pd group: * age \> 18 year-old * diagnosis of pd with onset \<2 years from enrollment * available dat spect performed in geneva university hospitals \<6 months before inclusion inclusion criteria for control group: age- and sex-matched control patients * age \> 18 year-old * no known neurological condition interfering with motor and cognitive abilities * no medication interfering with central nervous system (including antidepressants, antipsychotics, hypnotics) exclusion criteria for both groups: * major depressive state (hospital anxiety and depression scale ≥11 for depression score) * cognitive decline (mini-mental score ≤ 22/30) * debilitating tremor (movement disorders society - unified parkinson's disease rating scale (mds-updrs) part iii - rest, postural and action tremor ≥2/4) * significant akinesia (mds-updrs iii hand brady-akinesia score ≥2/4)
investigation of the frequency of hereditary hyper alpha-tryptasemia in patients with elevated basal tryptasemia

Conditions: Allergic Bronchiolitis

Summary: the aim of the study is to assess the number of patients with elevated blood tryptase for whom this elevation could be linked to a hereditary alpha-tryptase secretion abnormality or hyper-alpha-tryptasemia. this information will enable to better optimize the management and follow-up of patients who have experienced hypersensitivity reactions and have elevated basal blood tryptase levels. the patients will be offered the opportunity to take part in the study. if they consent to participate, they will be tested for hereditary hyper-alpha-tryptasemia. a blood sampling will be performed in the center. a few weeks after, the patient will be informed about the blood sample result during a medical consultation organized in the center.


Eligibility criteria:
inclusion criteria: * patients who came in the pneumoallergology department of the chu de nice since january 2014 for an allergological workup * patients who have received at least one basal tryptase assay, according to recommendations * informed consent signature exclusion criteria: * high tryptasemia (≥ 8ng/ml) synchronous with anaphylactic reaction and unconfirmed basally * known diagnosis of systemic mastocytosis
etiology of blood dyscrasias: analysis of the international agranulocytosis and aplastic anemia study data

Conditions: Anemia, Aplastic; Blood Disease; Agranulocytosis

Summary: to quantify the role of drugs and other factors in the etiology of agranulocytosis and aplastic anemia.

background: agranulocytosis and aplastic anemia are rare but serious blood diseases that can be caused by drugs and other environmental factors. in 1980, there were only limited quantitative estimates of the risk between various exposures, particularly drugs, and the two dyscrasias. the data were collected in the iaaas, a multicenter population-based case-control study conducted from 1980 to 1986 in eight regions. the study was funded by a pharmaceutical company to investigate a single hypothesis, but information was obtained on all drugs and on other factors, enabling a general investigation of the dyscrasias. design narrative: the study was for retrospective data analysis only. standard case-control methods were used. in most instances, multivariate analysis was used to control confounding, especially by simultaneous use of other causal drugs. adverse effects and the relative safety of drugs in relation to the two dyscrasias were documented. because the iaaas was population-based, incidence rates were provided directly, and excess risks were estimated for associated drugs. such quantitative measures of association were generally unavailable. among the drugs that were analyzed were various categories such as psychotropics, antihistamines, and cardiovascular drugs, and individual drugs such as allopurinol. factors other than drugs were also evaluated, including exposure to radiation and chemicals such as benzene and insecticides, history of viral infection, and history of allergy and other conditions. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
the purpose of the study is to examine whether iron deficiency anemia is associated with increased production of thrombin and whether correction of anemia by providing iron intravenously causes a significant reduction in production of thrombin.

Conditions: Iron Deficiency Anemias

Summary: in total 50 subjects with iron deficiency anemia treated with intravenous iron are planned for inclusion in this trial. after signing an informed consent a blood sample will be obtained from each participant before iron treatment. the investigators will measure the thrombin generation in plasma assessed by the calibrated automated thrombogram (cat). patient will go face to face interview and will be asked to answer structured questionnaire which will include information on demographics, clinical data ( fever, allergies , etc.) and comorbidities two weeks after completing intravenous iron administration additional blood samples will be taken: thrombin generation will be measured


Eligibility criteria:
inclusion criteria: * age \>18 years * iron deficiency anemia that did not response to oral iron treatment and is planned to receive iron supplement intravenously. * signing the informed consent exclusion criteria: * chronic inflammatory disease * renal failure * malignancy * infectious disease * other reason for anemia except iron deficiency anemia. * pregnant women * use of anti aggregating agents or anticoagulants

Keywords: anemias iron-deficiency thrombin
russian cardiovascular registry of covid-19

Conditions: Covid19; Acute Cardiovascular Disease; Cardiovascular Diseases

Summary: this is a russian multicenter observational study aimed to assess the mid-term and long-term prognosis in patients recovered from covid-19 with the involvement of the cardiovascular system or with baseline severe cardiovascular diseases.

this open multi-center observational study (registry) is designed to enroll consecutive eligible patients hospitalized with and recovered from covid-19 (icd-10 codes u07.1 or u07.2) with the involvement of the cardiovascular system or with baseline severe cardiovascular diseases. data collection is ongoing for the duration of the pandemic. this study aims to assess the mid-term and long-term prognosis in this patient population. analysis of this information may help to better predict the prognosis for patients and socio-economic burden of the coincidence of covid-19 and cardiovascular diseases and to better inform about the optimal surveillance programs in recovered patients. the de-identified participant data will be abstracted from the medical chart prospectively on the day of discharge or retrospectively (on the day of the first outpatient visit) and entered into an electronic database. the information will be stored in a database, and used at a later time for research studies. patients will be followed up for at least 12 months. data on standard clinical assessment, echocardiography, laboratory results, assessment of the current therapy, specific cardiovascular assessment (depending on the cardiovascular disease), and outcomes will be collected, as well as additional blood samples for biomarkers substudy and central core laboratory imaging assessment (when applicable) at 3, 6 and 12 months. the investigators will contact patients by telephone to obtain information about outcomes in case of inability to visit in person.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years of age 2. hospitalization with confirmed or suspected covid-19 (icd-10 codes u07.1 or u07.2) 3. involvement of the cardiovascular system or baseline severe cardiovascular diseases defined as at least of the following: * proven or suspected myocarditis; * heart failure (nyha functional class ii-iv) before or during hospitalization with covid-19; * combination of covid-19 with acs or development of acs during hospitalization with covid-19 or performed percutaneous coronary intervention; * proven pulmonary embolism; * hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the qt interval prolongation exclusion criteria: * none

Keywords: sars-cov-2 covid19 cardiovascular disease
haic combined with durvalumab and tremelimumab and lenvatinib in uhcc

Conditions: Hepatocellular Carcinoma

Summary: the treatment options for unresectable hcc have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma. the stride regimen of single tremelimumab (high, priming 300-mg dose) regular interval durvalumab (1500 mg every 4 weeks) improved os vs sorafenib in pts with unresectable hcc. in asian region, haic is applied for hcc patients who are not suitable for surgical resection or local ablation treatment. retrospective studies suggested a potent antitumor effect and survival benefit of haic plus programmed death-1 inhibitor and lenvatinib. this phase ii study was aimed to evaluate the efficacy and safety of stride plus lenvatinib, given concurrently with haic in pts with unresectable hcc.


Eligibility criteria:
inclusion criteria: 1. age 18 \~ 70 years old (including 70 years old), male and female; 2. patients with hepatohcellular carcinoma diagnosed clinically or confirmed by histology / cytology ; 3. patients with unresectable or metastatic hepatocellular carcinoma; 4. no systematic treatment. patients recieved previously systematic treatment and progressed can also be included in the group; 5. patients who underwent hepatectomy in the past should be r0 resection, and the tumor recurrence should be more than 6 months after operation; 6. at least one assessable lesion (mrecist criteria); 7. expected survival time ≥ 3 months; 8. ecog 0 \~ 1; 9. child pugh ≤ 7; 10. be able to cooperate to observe adverse events; 11. major organs are functioning normally: * hemoglobin ≥ 90 g / l; * anc ≥ 1.5 × 109/l； * platelet count ≥ 75 × 109/l； * albumin ≥ 28 g / l; * total bilirubin ≤ 2 × uln; * ast, alt ≤ 5 × uln； * alp ≤ 5 × uln； * creatinine ≤ 1.5 × uln； * inr or pt ≤ 1.5 × uln； j) aptt ≤ 1.5 × uln。 exclusion criteria: 1. history of symptomatic congestive heart failure, unstable angina pectoris, 2. uncontrolled cardia arrhythmia 3. history of hepatic encephalopathy 4. uncontrolled arterial hypertension 5. co-infection with hbv and hdv

Keywords: haic uhcc immunotherapy
effects of a diaphragmatic breathing training program in chronic obstructive pulmonary disease (copd) patients

Conditions: COPD

Summary: diaphragmatic dysfunction and alterations of thoracoabdominal motions are common in patients with chronic obstructive pulmonary disease (copd). several studies have described an impairment in diaphragmatic mobility of copd patients compared to age matched control subjects and it has been associated with increase in dyspnea, exercise intolerance and mortality. copd patients also experiment a higher activity of the accessory breathing muscles, which greatly increases the work of breathing and dyspnea sensation. breathing strategies have been considered an important component of pulmonary rehabilitation and refer to a range of techniques, including/which includes the diaphragmatic breathing (db). the principal aim of db is to improve the participation of the abdominal motion while reducing the accessory muscles activity. the role of db as an adjunctive treatment modality in the rehabilitation of copd patients remains controversial. despite the conflicting results, improvement of the abdominal motion and a reduction of thoracic excursion, during voluntarily db, has been described as a common finding of several studies. the investigators hypothesized that a 4-week dbtp could induce higher participation of the diaphragm and this modification would relieve respiratory symptoms and improve exercise tolerance and the hrqol. therefore, in this randomized controlled trial the investigators aimed to test the effects of a short-term dbtp on thoracoabdominal motion, pulmonary function, diaphragmatic mobility, dyspnea, hrqol and exercise tolerance in patients with mild to severe copd.


Eligibility criteria:
inclusion criteria: (1) age between 50 and 80 years; (2) a post-bronchodilator forced expiratory volume in one second (fev1) \< 80% of the predicted value and a fev1/ forced vital capacity (cvf) ratio \< 0,7; (3) stable respiratory/clinical condition without changes in medication and symptoms (dyspnea, volume or color of sputum) for at least 4 weeks before admission to the study; and (4) receiving regular treatment with inhaled bronchodilators and steroids. exclusion criteria: (1) presence of other pulmonary, cardiovascular or musculoskeletal diseases; (2) previously participation in any exercise-training program in the last 2 years before participating in this study; and (3) current smokers.

Keywords: copd, diaphragm, rehabilitation
an observational,prospective natural history study of early-onset extreme obesity due to bi-allelic loss-of-function mutations in the pomc, pcsk1 or lepr genes

Conditions: POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity

Summary: this is an observational study. there are no protocol-defined visits, although patients are expected to have routine office visits approximately every 6 months. upon signing of informed consent/assent and study enrollment, historical data will be abstracted from the patient's medical chart. the patient will then be observed prospectively for up to 5 years, with additional data collected from routine healthcare encounters and direct-to-patient questionnaires (where local laws allow), including laboratory tests, physical exam and patient reported outcomes/quality of life measures. patients will be consented/assented to provide blood samples for biomarker assessments, dna sequencing and archiving.


Eligibility criteria:
inclusion criteria: 1. age 2 years or older 2. study participant and/or parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and be able to understand and sign the written informed consent/assent. 3. have documented results of dna sequencing for the three genes of interest: pomc, pcsk1 and lepr. 4. bi-allelic, homozygous or compound heterozygous (a different gene mutation on each allele) genetic status for either the pomc or pcsk1 genes, resulting in a severe pomc deficiency obesity clinical phenotype, or a similar bi-allelic gene status for the lepr gene leading to identified lepr deficiency obesity. 5. patients who are willing to come in for routine office visits approximately every 6 months. exclusion criteria: 1. participation within the past 3 months in a clinical trial of any investigational medicine for obesity. 2. confirmed diagnosis of prader-willi syndrome, bardet-biedl syndrome, alström syndrome, or other syndromic form of genetic obesity.

Keywords: pomc lepr pcsk1 bi-allelic loss obesity